The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia

For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Here, we describe two patients with advanced CML who failed imatinib therapy and did not tolerate the recommended dose of dasatinib, but then achieved a maj...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yu, Pan, Liangqin, Hong, Ming, Liu, Weixing, Qiao, Chun, Li, Jianyong, Qian, Sixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Department of Journal of Biomedical Research 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138586/
https://www.ncbi.nlm.nih.gov/pubmed/27924071
http://dx.doi.org/10.7555/JBR.30.20130172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138586/
https://www.ncbi.nlm.nih.gov/pubmed/27924071
http://dx.doi.org/10.7555/JBR.30.20130172

Ejemplares similares